Lauxera Capital Partners
Paris-based healthcare growth-equity firm founded January 2020 specializing in European medtech, biotech and HealthTech scale-ups; deploys EUR 780M across Lauxera Growth I (vintage 2022 EUR 260M) and Lauxera Growth II (vintage 2025 EUR 520M oversubscribed hard cap of EUR 500M) with offices in Paris (41 Avenue de Friedland) and San Francisco (Mill Valley CA); notable exit OrganOx to Terumo USD 1.5bn October 2025.
Key facts
Recent exits
Coverage notes
2 funds tracked, 16 portfolio companies (15 active · 1 realized). Verified weekly from public filings and deal announcements.
Sector breakdown
16 companiesFunds & portfolio
Every fund Lauxera Capital Partners has raised, with its portfolio companies. Hand-checked from public filings.
Lauxera Growth IIGrowth2025 · 1yr€520M4 active
Unrealized
4 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Healthcare |  Germany | 2024 | |
| Healthcare |  Sweden | 2025 | |
| Healthcare |  US | 2026 | |
| Healthcare | Slovenia | 2026 |
Germany· Entry 2024Sweden· Entry 2025US· Entry 2026Lauxera Growth IGrowth2022 · 4yr€260M11 active · 1 realized
Unrealized
11 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech | Sweden | 2023 | |
| Healthcare | Germany | 2023 | |
| HealthTech |  France | 2021 | |
| Healthcare |  Netherlands | 2022 | |
| Healthcare | Germany | 2023 | |
| HealthTech | Sweden | 2024 | |
| Healthcare | France | 2024 | |
| MedTech |  Denmark | 2023 | |
| Healthcare | France | 2023 | |
| Healthcare | US | 2022 | |
| Healthcare | France | 2022 |
Sweden· Entry 2023Germany· Entry 2023France· Entry 2021Netherlands· Entry 2022Germany· Entry 2023Sweden· Entry 2024France· Entry 2024Denmark· Entry 2023France· Entry 2023US· Entry 2022France· Entry 2022
UKSaved GPs appear in your watchlist, one click from your workspace.
About Lauxera Capital Partners
Lauxera Capital Partners is a Paris-based healthcare growth equity firm with €660 million of assets under management as of December 2024, founded in January 2020. The firm specialises in European medtech, biotech and HealthTech scale-ups, deploying capital across Lauxera Growth I (vintage 2022, €260M) and Lauxera Growth II (vintage 2025, €400M) with selective offshore exposure to North American healthcare opportunities.
Investment thesis
Lauxera targets European healthcare growth equity in profitable medtech, biotech and HealthTech scale-ups, with equity tickets typically ranging from €20 million to €60 million per transaction. The growth equity mandate enables Lauxera to back profitable healthcare businesses seeking expansion capital rather than early-stage venture exposure, with the healthcare-exclusive focus providing clinical and regulatory expertise across portfolio companies.
Recent activity
Recent realised exits include OrganOx (healthcare, 2025), reflecting selective distribution activity across the healthcare growth portfolio. The platform tracks 2 funds and 13 active portfolio companies across the healthcare-exclusive programme. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
France·€800M
France·€800M
France·€800M
France·€800M
France·€740MFrance·€820M
France·€850M
France·€704M
France·€700M
France·€700M
France·€900MFrance·€906MGet the full picture on Lauxera Capital Partners.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in